![\"Video](\"https:\/\/www.dumonceau-urologie.fr\/wp-content\/uploads\/2026\/04\/j-ai-un-cancer-de-la-prostate-que-dois-je-faire-vtb-69e23817daf6b.jpg\")
<\/p>\n<\/p>\n
Receiving a prostate cancer<\/strong> diagnosis is always a difficult time. The first question that naturally comes to mind is simple: what should I do now?<\/strong><\/p>\n The answer is not the same for everyone. Today, prostate cancers are no longer treated systematically in the same way. Decisions are made based on the stage of the cancer<\/strong> , its risk level<\/strong> , but also on the individual patient.<\/p>\n Before treating cancer, you must treat a patient who has cancer<\/strong> . This distinction is essential, as it completely changes how you approach the options.<\/p>\n Treatment is never decided solely on a biopsy result or a PSA<\/a> level. Many personal factors must also be taken into account:<\/p>\n The final decision always rests with the patient, after they have received clear information about the available options. The urologist's role is to explain the realistic choices, their benefits, limitations, and potential consequences.<\/p>\n It's also important to keep in mind one key idea: the primary goal is to treat the cancer<\/strong> . The real enemy is the disease, not the treatment. Many men fear the side effects of treatment more than the cancer itself. This concern is understandable, but it shouldn't distract from the main objective.<\/p>\n Of course, future quality of life remains a central point. When considering treatment, particular attention is paid to:<\/p>\n The treatment of prostate cancer relies on very precise staging guidelines. These allow for a strategy tailored to the cancer's risk level.<\/p>\n These guidelines are used in a standardized way in France, in Europe and more broadly internationally. The objective is the same everywhere: to match the right treatment to the right stage<\/strong> .<\/p>\n Among the classifications used, we find in particular that of D'Amico<\/a><\/strong> , which makes it possible to distinguish between cancers with low risk, intermediate risk and high risk of progression or recurrence.<\/p>\n When it comes to low-risk prostate cancer<\/strong> , the most common management today is active surveillance<\/a><\/strong> .<\/p>\n In other words, we are not rushing into immediate treatment. This is not inaction, nor is it abandonment. It is a rigorous medical strategy that consists of closely monitoring the progression of the disease.<\/p>\n It relies on close monitoring including:<\/p>\n The idea is simple: to avoid unnecessary treatment in patients whose cancer is progressing slowly or only slightly, while retaining the possibility of intervening quickly if the situation changes.<\/p>\n Some men find it difficult to accept the idea of having cancer monitored, even when it is slow-growing. In this case, it is possible to discuss conventional curative treatment<\/strong> , such as:<\/p>\n Focal treatment may be considered in certain well-selected cases, depending in particular on age and the low-aggressive nature of the tumor.<\/p>\n When cancer is classified as intermediate risk<\/strong> , treatment is necessary. It is no longer simply a matter of routine monitoring.<\/p>\n Several options can then be offered.<\/p>\n The surgical treatment is prostatectomy<\/strong> , that is, the removal of the prostate. This surgery has evolved considerably over the last fifteen years, particularly with the development of robotic surgery<\/a><\/strong> .<\/p>\n Robot-assisted prostatectomy<\/strong> , particularly with theDa Vinci<\/a> robot, allows for more precise dissection. This precision is important for two reasons:<\/p>\n It is never advisable to promise the same result for everyone, as it depends on the type of cancer, the anatomy, the age, and the pre-operative situation. However, advances in surgical techniques have clearly improved the precision of the procedure.<\/p>\n Radiation therapy<\/a><\/strong> is another curative treatment option. It may be offered:<\/p>\n The choice between surgery and radiotherapy depends on the patient's profile, the characteristics of the cancer, and the therapeutic objectives chosen.<\/p>\n In some patients, focal treatment<\/strong> may also be considered. In a few very specific situations and within the context of studies, active surveillance<\/strong> may sometimes remain a possibility, but this is limited.<\/p>\n High-risk prostate cancers<\/strong> must be treated. At this stage, the goal is clearly to achieve the best possible control of the disease.<\/p>\n At a minimum, the following must be put in place:<\/p>\n However, in many cases, due to the aggressiveness of the cancer, combination therapy<\/strong> will be necessary. The most commonly recommended regimen is:<\/p>\n This strategy aims to strengthen the chances of local control and reduce the risk of recurrence when the disease presents more threatening characteristics.<\/p>\n Once the strategy has been decided upon between the patient and their urologist, this decision is validated by a committee of experts<\/strong> . This is now an essential rule in cancer care.<\/p>\n Each case is presented at a multidisciplinary consultation meeting<\/a><\/strong> , often abbreviated as RCP<\/a> .<\/p>\n In the case of prostate cancer, the following are generally found:<\/p>\n The goal is not to add complexity, but rather to ensure a sound decision. The case data is compared to current reference data to determine the best course of action<\/strong> .<\/p>\n The right treatment isn't just the one that exists on paper. It's the one that's appropriate.<\/p>\n The choice is therefore made at the intersection of two realities:<\/p>\n This is why there is no single universal answer to the question "What should I do?". However, there is a rigorous method for finding the most appropriate answer in each situation.<\/p>\n When faced with a prostate cancer diagnosis, it's normal to feel afraid, hesitant, and lost among several options. But it's important to stay focused: today, there are well-defined, structured treatment strategies tailored to each individual situation<\/strong> .<\/p>\n The most important thing is to have clear information, to understand the level of risk of one's cancer, and to build the decision with one's urologist on solid foundations.<\/p>\n The ideal treatment is neither the most intensive nor the most invasive. It is the one that effectively treats the illness while respecting, as much as possible, the patient's life afterward.<\/p>\n The starting point: personalizing the decision<\/h2>\n
\n
\n
Why the stage of cancer changes everything<\/h2>\n
Low-risk prostate cancer: active surveillance is often the best option<\/h2>\n
What does active surveillance consist of?<\/h3>\n
\n
What if the patient does not wish to simply be monitored?<\/h3>\n
\n
Intermediate-risk prostate cancer: treatment is necessary<\/h2>\n
Surgery: Prostatectomy<\/h3>\n
\n
Radiotherapy<\/h3>\n
\n
Focal treatment and, in rare cases, active monitoring<\/h3>\n
High-risk prostate cancer: essential treatment, often combined<\/h2>\n
\n
\n
A decision never made alone: the multidisciplinary consultation meeting<\/h2>\n
Who is participating in this meeting?<\/h3>\n
\n
How to choose between treatments?<\/h2>\n
\n
\n
Key takeaways<\/h2>\n
\n
A key idea for moving forward<\/h2>\n
Video<\/h2>\n<\/p>\n